Nirmatrelvir/Ritonavir

Kathryn Dzintars, Pharm.D., BCPS
Nirmatrelvir/Ritonavir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and pediatric (≥ 12 years of age) with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients > 60 years of age.

Paxlovid is NOT authorized for:

  • Initiation of treatment for patients requiring hospitalization
  • Pre-exposure or post-exposure prophylaxis for prevention of COVID-19
  • Use longer than 5 consecutive days

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and pediatric (≥ 12 years of age) with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients > 60 years of age.

Paxlovid is NOT authorized for:

  • Initiation of treatment for patients requiring hospitalization
  • Pre-exposure or post-exposure prophylaxis for prevention of COVID-19
  • Use longer than 5 consecutive days

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 4, 2022